Literature DB >> 1980694

Efficacy of benzodiazepines in panic disorder and agoraphobia.

J C Ballenger1.   

Abstract

Until recently, the benzodiazepines were believed to be ineffective in the treatment of panic disorder, with and without agoraphobic avoidance. Recent trials have shown, however, that panic disorder patients respond to benzodiazepines as well as to tricyclic antidepressants and monoamine oxidase (MAO) inhibitor antidepressants. Most of the controlled-trial investigations of benzodiazepines in panic disorder patients have evaluated the effects of alprazolam. However, early uncontrolled trials using other benzodiazepines have documented their effectiveness in panic disorder as well. This article reviews the evidence of the efficacy of alprazolam and other benzodiazepines in the treatment of panic disorder and their clinical use.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1980694     DOI: 10.1016/0022-3956(90)90032-l

Source DB:  PubMed          Journal:  J Psychiatr Res        ISSN: 0022-3956            Impact factor:   4.791


  4 in total

1.  Clinical and economic evaluation of benzodiazepines: a value analysis.

Authors:  J S Lyons; D B Larson; J Hromco
Journal:  Pharmacoeconomics       Date:  1992-11       Impact factor: 4.981

2.  Patterns and correlates of benzodiazepine use in the French general population.

Authors:  Rajaa Lagnaoui; Fanny Depont; Annie Fourrier; Abdelillah Abouelfath; Bernard Bégaud; Hélène Verdoux; Nicholas Moore
Journal:  Eur J Clin Pharmacol       Date:  2004-09       Impact factor: 2.953

3.  Panic disorder respiratory subtype: psychopathology and challenge tests - an update.

Authors:  Renata T Okuro; Rafael C Freire; Walter A Zin; Laiana A Quagliato; Antonio E Nardi
Journal:  Braz J Psychiatry       Date:  2020-02-14       Impact factor: 2.697

4.  Advancing the defensive explanation for anxiety disorders: lorazepam effects on human defense are systematically modulated by personality and threat-type.

Authors:  A M Perkins; U Ettinger; K Weaver; A Schmechtig; A Schrantee; P D Morrison; A Sapara; V Kumari; S C R Williams; P J Corr
Journal:  Transl Psychiatry       Date:  2013-04-16       Impact factor: 6.222

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.